PI3K/AKT Pathway As a Key Link Modulates the Multidrug Resistance of Cancers

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2020 Sep 25

PMID 32973135

Citations 309

Authors

Rui Liu

Youwen Chen

Guangzhi Liu

Chenxi Li

Yurong Song

Zhiwen Cao

Wen Li

Jinghong Hu

Cheng Lu

Yuanyan Liu

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth, and modulation of cellular metabolism. This review highlights the aberrant activation of PI3K/AKT as a key link that modulates MDR. We summarize the regulation of numerous major targets correlated with the PI3K/AKT pathway, which is further related to MDR, including the expression of apoptosis-related protein, ABC transport and glycogen synthase kinase-3 beta (GSK-3β), synergism with nuclear factor kappa beta (NF-κB) and mammalian target of rapamycin (mTOR), and the regulation of glycolysis.

Citing Articles

Polyethylene Glycolylation of the Purified Basic Protein (Protamine) of Squid (): Structural Changes and Evaluation of Proliferative Effects on Fibroblast.

Li N, Xu J, Li Y, Elango J, Wu W Int J Mol Sci. 2025; 26(5).

PMID: 40076495 PMC: 11899872. DOI: 10.3390/ijms26051869.

MAP17 contributes to the tumorigenesis of papillary thyroid carcinoma by activating the AKT signaling pathway.

Tian Z, Huang R, Li G, Zhu Y Arch Endocrinol Metab. 2025; 69(1):e240342.

PMID: 40062974 PMC: 11895518. DOI: 10.20945/2359-4292-2024-0342.

Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation.

Aslam A, Minshawi F, Almasmoum H, Almaimani R, Alsaegh A, Mahbub A J Egypt Natl Canc Inst. 2025; 37(1):7.

PMID: 40059278 DOI: 10.1186/s43046-025-00261-7.

Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action.

Zhou C, Wu K, Gu M, Yang Y, Tu J, Huang X Front Oncol. 2025; 15:1524182.

PMID: 40052129 PMC: 11882405. DOI: 10.3389/fonc.2025.1524182.

Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.

Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X Front Pharmacol. 2025; 16:1516583.

PMID: 40041495 PMC: 11877449. DOI: 10.3389/fphar.2025.1516583.

References

Sharma A . Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine (Lond). 2017; 12(17):2137-2148. DOI: 10.2217/nnm-2017-0184. View

Garcia-Mayea Y, Mir C, Masson F, Paciucci R, LLeonart M . Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol. 2019; 60:166-180. DOI: 10.1016/j.semcancer.2019.07.022. View

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

DeBerardinis R, Lum J, Hatzivassiliou G, Thompson C . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1):11-20. DOI: 10.1016/j.cmet.2007.10.002. View

Zhang X, Ai Z, Chen J, Yi J, Liu Z, Zhao H . Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway. Mol Med Rep. 2017; 15(4):1869-1876. DOI: 10.3892/mmr.2017.6189. View

Soltani A, Torki S, Ghahfarokhi M, Jami M, Ghatrehsamani M . Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells. Mol Biol Rep. 2019; 46(5):4809-4816. DOI: 10.1007/s11033-019-04929-x. View

Wu D, Zhang T, Liu Y, Deng S, Han R, Liu T . The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling. Cell Death Dis. 2019; 10(5):349. PMC: 6483988. DOI: 10.1038/s41419-019-1591-4. View

Ediriweera M, Tennekoon K, Samarakoon S . Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019; 59:147-160. DOI: 10.1016/j.semcancer.2019.05.012. View

Rahmani F, Ziaeemehr A, Shahidsales S, Gharib M, Khazaei M, Ferns G . Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J Cell Physiol. 2019; 235(5):4146-4152. DOI: 10.1002/jcp.29333. View

10.

Collier P . A practitioner comments on research findings. Understanding couvade. MCN Am J Matern Child Nurs. 1982; 7(2):114. View

11.

Ellis H, Ma C . PI3K Inhibitors in Breast Cancer Therapy. Curr Oncol Rep. 2019; 21(12):110. DOI: 10.1007/s11912-019-0846-7. View

12.

Rubinstein M, Hyman D, Caird I, Won H, Soldan K, Seier K . Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2019; 126(6):1274-1282. PMC: 7444087. DOI: 10.1002/cncr.32677. View

13.

De Marco C, Rinaldo N, Bruni P, Malzoni C, Zullo F, Fabiani F . Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS One. 2013; 8(2):e55362. PMC: 3567053. DOI: 10.1371/journal.pone.0055362. View

14.

Harding J, Nandakumar S, Armenia J, Khalil D, Albano M, Ly M . Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res. 2018; 25(7):2116-2126. PMC: 6689131. DOI: 10.1158/1078-0432.CCR-18-2293. View

15.

Millis S, Jardim D, Albacker L, Ross J, Miller V, Ali S . Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer. 2018; 125(7):1185-1199. PMC: 6433468. DOI: 10.1002/cncr.31921. View

16.

Wang D, Sun Y, Ye F, Li W, Kharbuja P, Gao L . Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells. Mol Cell Biochem. 2013; 386(1-2):143-52. DOI: 10.1007/s11010-013-1853-x. View

17.

Jin J, Xiong Y, Cen B . Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. Anticancer Drugs. 2017; 28(10):1141-1149. PMC: 5659308. DOI: 10.1097/CAD.0000000000000561. View

18.

Rocha G, Oliveira R, Kaplan M, Gattass C . 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. Eur J Pharmacol. 2014; 741:140-9. DOI: 10.1016/j.ejphar.2014.07.054. View

19.

House C, Jordan E, Hernandez L, Ozaki M, James J, Kim M . NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH Cancer Stem-like Cells. Cancer Res. 2017; 77(24):6927-6940. PMC: 5732863. DOI: 10.1158/0008-5472.CAN-17-0366. View

20.

Sui H, Pan S, Feng Y, Jin B, Liu X, Zhou L . Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway. BMC Complement Altern Med. 2014; 14:279. PMC: 4288643. DOI: 10.1186/1472-6882-14-279. View